ReviewActa pharmaceutica Sinica. B2022
Chemotherapeutic nanomaterials in tumor boundary delineation: Prospects for effective tumor treatment.
Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Artificial intelligence and machine learning-driven advancements in gastrointestinal cancer: Paving the way for precision medicine.World journal of gastroenterology · 2026Review
- From nanotags to precision biomedicine: SERS-driven progress and innovation in tumor biomarker profiling, dynamic bioimaging, AI-enhanced diagnostics and therapy.Theranostics · 2026Review
- Engineering Bacterial Secretion Systems for Enhanced Tumor Imaging and Surgical Guidance.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Applications of magnetic nanoparticles for boundarics in biomedicine.Fundamental research · 2025Review
- Nanomaterial-Based Molecular Imaging in Cancer: Advances in Simulation and AI Integration.Biomolecules · 2025Review
- Surgery versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced gastrointestinal tract cancers.Frontiers in oncology · 2025Article
- Optimized Synthetic Correlated Diffusion Imaging for Improving Breast Cancer Tumor Delineation.Sensors (Basel, Switzerland) · 2024Article
- Nano-formulated delivery of active ingredients from traditional Chinese herbal medicines for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2024Review
- Targeting Tumor-Associated Macrophages for Imaging.Pharmaceutics · 2022Review
- Editorial of Special Column on A New Era of Nanobiomaterial-based Drug Delivery.Acta pharmaceutica Sinica. B · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurately delineating tumor boundaries is key to predicting survival rates of cancer patients and assessing response of tumor microenvironment to various therapeutic techniques such as chemotherapy and radiotherapy. This review discusses various strategies that have been deployed to accurately delineate tumor boundaries with particular emphasis on the potential of chemotherapeutic nanomaterials in tumor boundary delineation. It also compiles the types of tumors that have been successfully delineated by currently available strategies. Finally, the challenges that still abound in accurate tumor boundary delineation are presented alongside possible perspective strategies to either ameliorate or solve the problems. It is expected that the information communicated herein will form the first compendious baseline information on tumor boundary delineation with chemotherapeutic nanomaterials and provide useful insights into future possible paths to advancing current available tumor boundary delineation approaches to achieve efficacious tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.